Mr. Steinkrauss is the founder of OWL CFO Consulting, a consulting firm providing part-time CFO services to companies in the biotechnology industry. He previously served as CFO and chief administrative officer of Curis, a publicly traded biotechnology company.
In his new role, Mr. Steinkrauss will lead financial strategy and operations as OcuTerra advances its lead asset for the treatment of diabetic retinopathy, OTT166.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.